Vivet Therapeutics, supported by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals

by Ysios Capital

​ Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Viv...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

by Labo'Life

Photos Stream